Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.31 |
| ▸ | CDC25B | P30305 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19200948 | 0.95 | LMNA (0.63) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL24158176 | 0.95 | LMNA (0.72) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL9275725 | 0.92 | LMNA (0.68) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL7765946 | 0.92 | LMNA (0.67) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL5586167 | 0.89 | LMNA (0.72) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL18897541 | 0.89 | LMNA (0.93) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL2985725 | 0.86 | LMNA (1.00) | LMNABLMPTPN1MEN1CYP3A4 | |
| Squalane SCHEMBL4708649 | 0.86 | LMNA (1.00) | LMNABLMPTPN1MEN1CYP3A4 | |
| Squalane SCHEMBL15449 | 0.86 | LMNA (1.00) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL29030039 | 0.86 | LMNA (1.00) | LMNABLMPTPN1MEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3122455-B1 | DEWAXING METHOD USING TITANIA-CONTAINING ZSM-48 | EXXONMOBIL RES & ENG CO (US) | 2019-03-27 | — | — | EP | disclosed |
| EP-3122455-A2 | SYNTHESIS OF FRAMEWORK MODIFIED ZSM-48 CRYSTALS | ExxonMobil Research and Engineering Company (US) | 2017-02-01 | — | — | EP | disclosed |
| US-9433935-B2 | Synthesis of framework modified ZSM-48 crystals | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2016-09-06 | — | — | US | disclosed |
| CN-105853417-A | Application of aconitine in treating lupus erythematosus | 中国中医科学院中药研究所 | 2016-08-17 | — | — | CN | disclosed |
| US-20150273450-A1 | SYNTHESIS OF FRAMEWORK MODIFIED ZSM-48 CRYSTALS | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2015-10-01 | — | — | US | disclosed |
| US-20110206671-A1 | AXON REGENERATION PROMOTER | YAMASHITA TOSHIHIDE | 2011-08-25 | — | — | US | disclosed |
| US-20080182976-A1 | Antibodies which activate an erythropoietin receptor | AMGEN INC. | 2008-07-31 | — | — | US | disclosed |
| US-20070253946-A1 | Axon Regeneration Promoter | BIOCLUES, INC. (JP) | 2007-11-01 | — | — | US | disclosed |
| EP-1146056-B1 | Antibodies which activate an erythropoietin receptor | AMGEN INC (US) | 2007-03-07 | — | — | EP | disclosed |
| US-20070014793-A1 | Antibodies which activate an erythropoietin receptor | AMGEN INC. | 2007-01-18 | — | — | US | disclosed |
| EP-1733737-A1 | AXON REGENERATION PROMOTER | Bioclues, Inc. (JP) | 2006-12-20 | — | — | EP | disclosed |
| US-7081523-B2 | Antibodies which activate an erythropoietin receptor | AMGEN INC. (US) | 2006-07-25 | — | — | US | disclosed |
| US-20030215444-A1 | Antibodies which activate an erythropoietin receptor | AMGEN INC. | 2003-11-20 | — | — | US | disclosed |
| EP-0773962-B1 | ANTIBODIES WHICH ACTIVATE AN ERYTHROPOIETIN RECEPTOR | AMGEN INC (US) | 2001-11-21 | — | — | EP | disclosed |
| US-6319499-B1 | ADMINISTERING AMOUNT OF ANTIBODY OR FRAGMENT THEREOF EFFECTIVE TO ACTIVATE ENDOGENOUS ACTIVITY OF ERYTHROPOIETIN RECEPTOR IN MAMMAL, WHEREIN ANTIBODY OR FRAGMENT THEREOF INTERACTS WITH PEPTIDE CONSISTING OF SPECIFIED AMINO ACID SEQUENCE | AMGEN INC. | 2001-11-20 | — | — | US | disclosed |
| EP-1146056-A1 | Antibodies which activate an erythropoietin receptor | Amgen, Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| US-5885574-A | PRODUCED BY HYBRIDOMA CELL LINE ATCC NO.IIB11689 OR ATCC NO. IIB11690 OR A FRAGMENT; USEFUL FOR TREATMENT OF ANEMIA | AMGEN INC. (US) | 1999-03-23 | — | — | US | disclosed |
| EP-0773962-A1 | ANTIBODIES WHICH ACTIVATE AN ERYTHROPOIETIN RECEPTOR | AMGEN INC. (US) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996003438-A1 | ANTIBODIES WHICH ACTIVATE AN ERYTHROPOIETIN RECEPTOR | AMGEN INC. (US) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110206671-A1 | AXON REGENERATION PROMOTER | DRG1, DCX, GAP43 | LMNA 2255/4885BLM 4395/4885PTPN1 4236/4885 |
| US-20070253946-A1 | Axon Regeneration Promoter | DRG1, DCX, GAP43 | LMNA 2255/4885BLM 4395/4885PTPN1 4236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.